CASGEVY Makes History as FDA Approves First CRISPR/Cas9 Genome Edited Therapy

Vertex Pharmaceuticals and CR , ISPR Therapeutics . Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Sickle Cell Disease. December 8, 2023. Available from: https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval [Last accessed: December 12, 2023].

Editas Medicine. Form 8-K. December 13, 2023. Available from: https://ir.editasmedicine.com/static-files/00ffa25f-ac7b-480b-b163-ee509e2ba450 [Last accessed: December 15, 2023].

Gray V. LinkedIn Post. December 8, 2023. Available from: https://www.linkedin.com/posts/victoria-gray-3875442a1_words-cannot-express-the-level-of-joy-and-activity-7138950371305037824-mBcP

Bluebird Bio. Bluebird Bio Announces FDA Approval of LYFGENIA™ (Lovotibeglogene Autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events. December 8, 2023. Available from: https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-approval-lyfgeniatm-lovotibeglogene [Last accessed: December 12, 2023].

Tome Biosciences. Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform. December 12, 2023. Available from: https://tome.bio/wp-content/uploads/2023/12/pr-2023-12-12_Tome-Biosciences-Launches-with-Over-200-Million-in-Funding.pdf [Last accessed: December 12, 2023].

U.S. Food and Drug Administration. FDA Investigating Serious Risk of T-Cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies. November 28, 2023. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous [Last accessed: December 12, 2023].

Philippidis A. StockWatch: CAR-T Shares Mostly Flat as FDA Probes Risk of New Cancers. Genetic Engineering & Biotechnology News. December 1, 2023. Available from: https://www.genengnews.com/gen-edge/stockwatch-car-t-shares-mostly-flat-as-fda-probes-risk-of-new-cancers/ [Last accessed: December 12, 2023].

Oxford Biomedica. Oxford Biomedica Signs Agreement to Acquire ABL Europe from Institut Mérieux, Consolidating Position as a Global Pure-Play CDMO. December 4, 2023. Available from: https://oxb.com/oxford-biomedica-signs-agreement-to-acquire-abl-europe-from-institut-merieux-consolidating-position-as-a-global-pure-play-cdmo/ [Last accessed: December 12, 2023].

Kamau Therapeutics. Kamau Therapeutics Emerges from Stealth with Clinical-Stage Novel Gene Correction Technology Targeting Life-Threatening Genetic Diseases. December 7, 2023. Available from: https://kamautx.com/kamau-therapeutics-emerges-from-stealth-with-clinical-stage-novel-gene-correction-technology-targeting-life-threatening-genetic-diseases/ [Last accessed: December 15, 2023].

Grinstein J. A Sickle Sequel: Matthew Porteus Launches Kamau with Positive Nula-Cell Patient Zero Results. Genetic Engineering & Biotechnology News. December 11, 2023. Available from: https://www.genengnews.com/topics/genome-editing/a-sickle-sequel-matthew-porteus-launches-kamau-with-positive-nula-cell-patient-zero-results/ [Last accessed: December 15, 2023].

Shyr DC , Lowsky R , Miller W , et al. One Year Follow-Up on the First Patient Treated with Nula-Cel: An Autologous CRISPR/Cas9 Gene Corrected CD34+ Cell Product to Treat Sickle Cell Disease. Abstract 5000, 2023 Annual Meeting of the American Society of Hematology (ASH). Available from: https://ash.confex.com/ash/2023/webprogram/Paper188963.html [Last accessed: December 15, 2023].